Cardiovascular
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Anthos Takes On Pharma Giants In Factor XI Anticoagulation Space
CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.
AdipoPharma Targets Root Cause Of Diabetes With First ‘Adipeutic’ Drug Candidate
Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.
Bayer Backs Eylea's Prospects Despite Lucentis Biosimilars
Competition, both branded and generic, is on the rise but the German group believes that Eylea will continue to outperform given its safety and efficacy profile and the potential of a longer-lasting version of the eye therapy.
Alnylam Ready To Expand TTR Franchise With Positive Cardiomyopathy Results
ATTR amyloidosis patients with cardiomyopathy had statistically significant functional and quality of life improvements when treated with Onpattro (patisiran) in the Phase III APOLLO-B study.
On A Roll, AstraZeneca Aims For ‘Industry-Leading’ Growth From 2025
AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.
Bristol’s New Products Meet Early Launch Expectations
Sales rose significantly for Reblozyl and for Abecma and Breyanzi, despite manufacturing challenges for the two cell therapies. Newly approved Opdualag and Camzyos are off to encouraging starts.
Leqvio Sales Still Lag But Novartis Is Playing The Long Game
The twice-yearly cholesterol injectable approved in Europe 18 months ago is still not making any commercial headway but Novartis's CEO Vas Narasimhan has stressed that the groundwork for access to and education about Leqvio is being firmly laid.
Verve Hits The Clinic With Gene-Edited Cholesterol-Lowering Drug
The company dosed the first patient in its study of base editor VERVE-101, a possible single-dose treatment for HeFH that joins a growing list of PCSK9-targeted therapy candidates.
NewAmsterdam Is Behind Another Try At CETP Inhibition, With Menarini’s Help
Years after failures by Merck, Lilly, Pfizer and Roche, NewAmsterdam hopes to bring a CETP inhibitor to market to lower cholesterol, and signs on with Menarini to lead commercial efforts in Europe.
AstraZeneca Closes Amyloidosis Gap On Alnylam After Eplontersen Win
AstraZeneca is preparing a US filing for hereditary transthyretin-mediated amyloid polyneuropathy for eplontersen, which it hopes will compete with Pfizer and Alnylam's therapies in that rare disease space.
Amgen To Rapidly Move Olpasiran Into Phase III For Lp(a) Reduction
The siRNA drug demonstrated a significant reduction in lipoprotein(a) from baseline of up to or greater than 90% for the majority of doses in a Phase II trial; Novartis has a potential first-to-market advantage.
Healios, Athersys Confident Despite Missed Japan Stroke Endpoint
A missed primary endpoint in new top-line results from a Japanese trial with the stem cell therapy for stroke MultiStem hits Athersys and Japanese partner hard, casting a shadow over ongoing studies.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.